Literature DB >> 18070707

Genetic events in the pathogenesis of multiple myeloma.

W J Chng1, O Glebov, P L Bergsagel, W M Kuehl.   

Abstract

The genetics of myeloma has been increasingly elucidated in recent years. Recurrent genetic events, and also biologically distinct and clinically relevant genetic subtypes of myeloma have been defined. This has facilitated our understanding of the molecular pathogenesis of the disease. In addition, some genetic abnormalities have proved to be highly reproducible prognostic factors. With the expanding therapeutic armamentarium, it is time to include genetic assessment as part of clinical evaluation of myeloma patients to guide management. In this review we examine the role of various genetic abnormalities in the molecular pathogenesis of myeloma, and the use of such abnormalities in disease classification, prognosis and clinical management.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18070707      PMCID： PMC2198931          DOI： 10.1016/j.beha.2007.08.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  103 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  R Fonseca; M M Oken; P R Greipp
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

3.  ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.

Authors:  Atsushi Suzuki; Shinsuke Iida; Miyuki Kato-Uranishi; Emi Tajima; Fenghuang Zhan; Ichiro Hanamura; Yongsheng Huang; Tsutomu Ogura; Satoru Takahashi; Ryuzo Ueda; Bart Barlogie; John Shaughnessy; Hiroyasu Esumi
Journal:  Oncogene       Date:  2005-10-20       Impact factor: 9.867

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.

Authors:  J Shaughnessy; E Tian; J Sawyer; K Bumm; R Landes; A Badros; C Morris; G Tricot; J Epstein; B Barlogie
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

6.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

Authors:  Thomas Rasmussen; Michael Kuehl; Marianne Lodahl; Hans E Johnsen; Inger Marie S Dahl
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

8.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.

Authors:  Hong Chang; Stephen Sloan; Dan Li; Lihua Zhuang; Qi-Long Yi; Christine I Chen; Donna Reece; Kathy Chun; A Keith Stewart
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

9.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701
View more
  71 in total

1.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Authors:  Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Rebecca K M Protheroe; David M Stockley; Christine J Harrison; Nicholas C P Cross; Alex J Szubert; Mark T Drayson; Gareth J Morgan
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

Review 2.  Malleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

3.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

Review 4.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

5.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

Review 6.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

7.  Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression.

Authors:  Lei Zhang; Lin Zhou; Meng Shi; Yong Kuang; Lei Fang
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

8.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

9.  Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Authors:  Yulia N Demchenko; Oleg K Glebov; Adriana Zingone; Jonathan J Keats; P Leif Bergsagel; W Michael Kuehl
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

10.  The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Authors:  Manik Chatterjee; Mindaugas Andrulis; Thorsten Stühmer; Elisabeth Müller; Claudia Hofmann; Torsten Steinbrunn; Tanja Heimberger; Heike Schraud; Stefanie Kressmann; Hermann Einsele; Ralf C Bargou
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.